Praxis Precision Medicines' ulixacaltamide (PRAX-944) fails to achieve statistical significance in primary endpoint for essential tremor treatment in Phase 2 clinical trial. The drug demonstrates ...
Designed to meet demand for practical faith-based investing that’s lower cost, transparent, tax-efficient—without compromising investment performance results “Our new active ETFs are designed to meet ...
Praxis Precision Medicines’ challenge to Sage Therapeutics has unraveled. With a phase 2/3 clinical trial in major depressive disorder (MDD) failing comprehensively, Praxis is stopping work on a ...
A committee of outside clinical trial observers has recommended that Praxis Precision Medicines stop testing its experimental treatment for essential tremor after an interim analysis of one study ...
Praxis Precision Medicines has scored another midphase win in epilepsy this year, with its sodium channel inhibitor shown to reduce seizures in children with two specific types of the neurological ...
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Designed to meet demand for practical faith-based investing that’s lower cost, transparent, tax-efficient—without compromising investment performance results GOSHEN, Ind., April 08, 2025--(BUSINESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback